Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model

The development of tyrosine kinase inhibitors (TKIs) has improved the treatment of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. The current research priority is to provide viable treatments for patients who have drug-resistant EGFR mutations. We evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikeuchi, Hiroshi, Hirose, Takeshi, Ikegami, Masachika, Takamochi, Kazuya, Suzuki, Kenji, Mano, Hiroyuki, Kohsaka, Shinji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9033582/
https://www.ncbi.nlm.nih.gov/pubmed/35304574
http://dx.doi.org/10.1038/s41388-022-02263-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9033582/
https://www.ncbi.nlm.nih.gov/pubmed/35304574
http://dx.doi.org/10.1038/s41388-022-02263-4

Ejemplares similares